For the Lastest News Sign up mobilsocial

VIVUS Accelerates the Launch of Telemedicine and Remote …

VIVUS

VIVUS Accelerates the Launch of Telemedicine and Remote …

Virtual office visits and smart health devices available through the VIVUS Health Platform give physicians new tools for optimizing patient care and protecting the …

VIVUS Accelerates the Launch of Telemedicine and Remote Monitoring Modules to Facilitate Effective Patient Care During “Social Distancing”Search to view your mailU.S. markets close in 6 hours 8 minutes2,601.12-25.53(-0.97%)22,115.25-212.23(-0.95%)7,728.38-45.78(-0.59%)VIVUS Accelerates the Launch of Telemedicine and Remote Monitoring Modules to Facilitate Effective Patient Care During “Social Distancing”March 31, 2020.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Forward-Looking Statements” data-reactid=”27″>Forward-Looking Statements

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks, uncertainties and other factors, including risks and uncertainties related to our ability to execute on our business strategy to enhance long-term stockholder value; risks and uncertainties related to our ability to address our outstanding balance of the convertible notes due in May 2020; risk and uncertainties related to the timing, strategy, structure and success of our capital raising efforts; risks and uncertainties related to the effect of the recent coronavirus (COVID-19) outbreak on our business and the businesses of our partners; risks and uncertainties related to the effectiveness of the VIVUS Health Platform, including its adoption by healthcare providers and its ability to improve patient outcomes and, if applicable, access to Qsymia® and PANCREAZE®; risks and uncertainties related to the timing, strategy, tactics and success of the marketing and sales of PANCREAZE, including our ability to improve patient access to PANCREAZE; risks and uncertainties related to our, or our current or potential partner's, ability to successfully commercialize Qsymia, including our ability to improve patient and physician access to Qsymia; risks and uncertainties related to our ability to sell through the Qsymia retail pharmacy network and the Qsymia Advantage Program; risks and uncertainties related to the timing of initiation and completion of the post-approval clinical studies required as part of the approval of Qsymia by the U.S. Food and Drug Administration (“FDA”), including the Phase 4 post-marketing study of Qsymia in obese adolescents; risks and uncertainties related to the response from FDA to any data and/or information relating to post-approval clinical studies required for Qsymia; risks and uncertainties related to the impact of any possible future requirement to provide further analysis of previously submitted clinical trial data; risks and uncertainties related to the design and outcome of any clinical study required by FDA to expand the Qsymia label; risks and uncertainties related to our ability to work with FDA to significantly reduce or remove the requirements of the clinical post-approval cardiovascular outcomes trial; risks and uncertainties related to the failure to obtain FDA or foreign authority clearances or approvals and noncompliance with FDA or foreign authority regulations; and risks and uncertainties related to our ability to demonstrate through clinical testing the quality, safety, and efficacy of our current or future investigational drug candidates or approved products. These risks and uncertainties could cause actual results to differ materially from those referred to in these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. Investors should read the risk factors set forth in VIVUS’ Form 10-K for the year ended December 31, 2019 as filed on March 3, 2020, and periodic reports filed with the Securities and Exchange Commission. VIVUS does not undertake an obligation to update or revise any forward-looking statements.” data-reactid=”28″>Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks, uncertainties and other factors, including risks and uncertainties related to our ability to execute on our business strategy to enhance long-term stockholder value; risks and uncertainties related to our ability to address our outstanding balance of the convertible notes due in May 2020; risk and uncertainties related to the timing, strategy, structure and success of our capital raising efforts; risks and uncertainties related to the effect of the recent coronavirus (COVID-19) outbreak on our business and the businesses of our partners; risks and uncertainties related to the effectiveness of the VIVUS Health Platform, including its adoption by healthcare providers and its ability to improve patient outcomes and, if applicable, access to Qsymia® and PANCREAZE®; risks and uncertainties related to the timing, strategy, tactics and success of the marketing and sales of PANCREAZE, including our ability to improve patient access to PANCREAZE; risks and uncertainties related to our, or our current or potential partner’s, ability to successfully commercialize Qsymia, including our ability to improve patient and physician access to Qsymia; risks and uncertainties related to our ability to sell through the Qsymia retail pharmacy network and the Qsymia Advantage Program; risks and uncertainties related to the timing of initiation and completion of the post-approval clinical studies required as part of the approval of Qsymia by the U.S. Food and Drug Administration (“FDA”), including the Phase 4 post-marketing study of Qsymia in obese adolescents; risks and uncertainties related to the response from FDA to any data and/or information relating to post-approval clinical studies required for Qsymia; risks and uncertainties related to the impact of any possible future requirement to provide further analysis of previously submitted clinical trial data; risks and uncertainties related to the design and outcome of any clinical study required by FDA to expand the Qsymia label; risks and uncertainties related to our ability to work with FDA to significantly reduce or remove the requirements of the clinical post-approval cardiovascular outcomes trial; risks and uncertainties related to the failure to obtain FDA or foreign authority clearances or approvals and noncompliance with FDA or foreign authority regulations; and risks and uncertainties related to our ability to demonstrate through clinical testing the quality, safety, and efficacy of our current or future investigational drug candidates or approved products. These risks and uncertainties could cause actual results to differ materially from those referred to in these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. Investors should read the risk factors set forth in VIVUS’ Form 10-K for the year ended December 31, 2019 as filed on March 3, 2020, and periodic reports filed with the Securities and Exchange Commission. VIVUS does not undertake an obligation to update or revise any forward-looking statements.

VIVUS, Inc. Investor Relations: Lazar FINN Partners Mark Oki David Carey Chief Financial Officer Senior Partner 650-934-5200  212-867-1768 <p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content=".gnwlistitemmarginbottom {margin-bottom: 10.0px ;} .gnwtablebottommargin {margin-bottom: 10.0px ;} .gnwcellpaddingleft0 {padding-left: 0.0px ;} .gnwverticalaligntop {vertical-align: top ;} .gnwtextaligncenter {text-align: center ;} .gnwcellparagraphmargin {margin-bottom: 0px ; margin-top: 0px ;} .gnwverticalalignbottom {vertical-align: bottom ;} .gnwwhitespacenowrap {white-space: nowrap ;} .gnwtextalignright {text-align: right ;} .gnwcellpaddingright0 {padding-right: 0.0px ;} .gnwunderlinestyle {text-decoration: underline ;} .gnwtextalignleft {text-align: left ;} .gnw_ol {position: relative ; left: 10px ;} .gnw_ul {position: relative ; left: 10px ;} .gnw_table_border_collapse td {font-size: 12px ; line-height: 1.25em ;} .gnw_border_top_solid {border-top: solid black 1px ;} .gnw_border_right_solid {border-right: solid black 1px ;} .gnw_border_bottom_solid {border-bottom: solid black 1px ;} .gnw_border_left_solid {border-left: solid black 1px ;} .gnw_border_top_double {border-top: double black 3px ;} .gnw_border_right_double {border-right: double black 3px ;} .gnw_border_bottom_double {border-bottom: double black 3px ;} .gnw_border_left_double {border-left: double black 3px ;} .gnw_table_border_collapse {border-collapse: collapse ;} .gnw_align_left {text-align: left ;} .gnw_align_center {text-align: center ;} .gnw_align_right {text-align: right ;} .gnw_align_justify {text-align: justify ;} .gnw_vertical_align_top {vertical-align: top ;} .gnw_vertical_align_middle {vertical-align: middle ;} .gnw_vertical_align_bottom {vertical-align: bottom ;} .gnw_padding_left_none {padding-left: 0 ;} .gnw_padding_right_none {padding-right: 0 ;} .gnw_table_border_collapse td.gnw_align_left {padding-left: 0 ;padding-right: 3px ;} .gnw_table_border_collapse td.gnw_align_right {padding-left: 3px ;padding-right: 0 ;} .gnw_heading {font: 16px Arial; text-align: center ;} .gnw_subhead {font: 12px Arial; text-align: center ;} .gnw_colhead {font: 12px Arial; text-align: center ;} .gnw_colhead_uline {font: 12px Arial; text-align: center ; border-bottom: solid black 1.0pt;} .gnw_colhead_dline {font: 12px Arial; text-align: center ; border-bottom: double black 2.5pt;} .gnw_label {font: 12px Arial; vertical-align: bottom ; text-align: left ;} .gnw_label_uline {font: 12px Arial; vertical-align: bottom ; text-align: left ; border-bottom: solid black 1.0pt;} .gnw_label_uline_i10 {font: 12px Arial; vertical-align: bottom ; text-align: left ; border-bottom: solid black 1.0pt; padding-left: 10.0px;} .gnw_label_uline_i15 {font: 12px Arial; vertical-align: bottom ; text-align: left ; border-bottom: solid black 1.0pt; padding-left: 15.0px;} .gnw_label_uline_i20 {font: 12px Arial; vertical-align: bottom ; text-align: left ; border-bottom: solid black 1.0pt; padding-left: 20.0px;} .gnw_label_uline_i25 {font: 12px Arial; vertical-align: bottom ; text-align: left ; border-bottom: solid black 1.0pt; padding-left: 25.0px;} .gnw_label_uline_i30 {font: 12px Arial; vertical-align: bottom ; text-align: left ; border-bottom: solid black 1.0pt; padding-left: 30.0px;} .gnw_label_dline_i10 {font: 12px Arial; vertical-align: bottom ; text-align: left ; border-bottom: double black 2.5pt; padding-left: 10.0px;} .gnw_label_dline_i15 {font: 12px Arial; vertical-align: bottom ; text-align: left ; border-bottom: double black 2.5pt; padding-left: 15.0px;} .gnw_label_dline_i20 {font: 12px Arial; vertical-align: bottom ; text-align: left ; border-bottom: double black 2.5pt; padding-left: 20.0px;} .gnw_label_dline_i25 {font: 12px Arial; vertical-align: bottom ; text-align: left ; border-bottom: double black 2.5pt; padding-left: 25.0px;} .gnw_label_dline_i30 {font: 12px Arial; vertical-align: bottom ; text-align: left ; border-bottom: double black 2.5pt; padding-left: 30.0px;} .gnw_label_ulinetop {font: 12px Arial; vertical-align: bottom ; text-align: left ; border-top: solid black 1.0pt;} .gnw_label_dline {font: 12px Arial; vertical-align: bottom ; text-align: left ; border-bottom: double black 2.5pt;} .gnw_label_i10 {font: 12px Arial; vertical-align: bottom ; text-align: left ; padding-left: 10.0px;} .gnw_label_i15 {font: 12px Arial; vertical-align: bottom ; text-align: left ; padding-left: 15.0px;} .gnw_label_i20 {font: 12px Arial; vertical-align: bottom ; text-align: left ; padding-left: 20.0px;} .gnw_label_i25 {font: 12px Arial; vertical-align: bottom ; text-align: left ; padding-left: 25.0px;} .gnw_label_i30 {font: 12px Arial; vertical-align: bottom ; text-align: left ; padding-left: 30.0px;} .gnw_num {font: 12px Arial; vertical-align: bottom ; text-align: right ; white-space: nowrap ;} .gnw_num_uline {font: 12px Arial; vertical-align: bottom ; text-align: right ; white-space: nowrap ; border-bottom: solid black 1.0pt;} .gnw_num_ulinetop {font: 12px Arial; vertical-align: bottom ; text-align: right ; white-space: nowrap ; border-top: solid black 1.0pt;} .gnw_num_dline {font: 12px Arial; vertical-align: bottom ; text-align: right ; white-space: nowrap ; border-bottom: double black 2.5pt;} .gnw_num_dlinetop {font: 12px Arial; vertical-align: bottom ; text-align: right ; white-space: nowrap ; border-top: double black 2.5pt;} .gnw_data {font: 12px Arial; vertical-align: bottom ; text-align: left ; white-space: nowrap ;} .gnw_data_uline {font: 12px Arial; vertical-align: bottom ; text-align: left ; border-bottom: solid black 1.0pt;} .gnw_data_dline {font: 12px Arial; vertical-align: bottom ; text-align: left ; border-bottom: double black 2.5pt;} .gnw_news_media_box {margin-top: 15px ; margin-left: 6px ; margin-bottom: 6px ; margin-right: 6px ; border-width: 1px ; border-color: #A9A9A9 ; border-style: solid ;} .gnw_media_caption {font-size: 8pt ; font-family: Verdana, Arial, Helvetica, Geneva, Swiss, SunSans-Regular ;} .gnw_media_bgcolor {background-color: transparent ;} .gnw_table {border-collapse: separate ; border-spacing: 6px ;} .gnw_videotitle {font: bold 12px Arial ; color: #1d5296 ;} td.gnw_heading {font: 16px Arial; text-align: center ;} td.gnw_subhead {font: 12px Arial; text-align: center ;} td.gnw_colhead {font: 12px Arial; text-align: center ;} td.gnw_colhead_uline {font: 12px Arial; text-align: center ; border-bottom: solid black 1.0pt;} td.gnw_colhead_dline {font: 12px Arial; text-align: center ; border-bottom: double black 2.5pt;} td.gnw_label {font: 12px Arial; vertical-align: bottom ; text-align: left ;} td.gnw_label_uline {font: 12px Arial; vertical-align: bottom ; text-align: left ; border-bottom: solid black 1.0pt;} td.gnw_label_uline_i10 {font: 12px Arial; vertical-align: bottom ; text-align: left ; border-bottom: solid black 1.0pt; padding-left: 10.0px;} td.gnw_label_uline_i15 {font: 12px Arial; vertical-align: bottom ; text-align: left ; border-bottom: solid black 1.0pt; padding-left: 15.0px;} td.gnw_label_uline_i20 {font: 12px Arial; vertical-align: bottom ; text-align: left ; border-bottom: solid black 1.0pt; padding-left: 20.0px;} td.gnw_label_uline_i25 {font: 12px Arial; vertical-align: bottom ; text-align: left ; border-bottom: solid black 1.0pt; padding-left: 25.0px;} td.gnw_label_uline_i30 {font: 12px Arial; vertical-align: bottom ; text-align: left ; border-bottom: solid black 1.0pt; padding-left: 30.0px;} td.gnw_label_dline_i10 {font: 12px Arial; vertical-align: bottom ; text-align: left ; border-bottom: double black 2.5pt; padding-left: 10.0px;} td.gnw_label_dline_i15 {font: 12px Arial; vertical-align: bottom ; text-align: left ; border-bottom: double black 2.5pt; padding-left: 15.0px;} td.gnw_label_dline_i20 {font: 12px Arial; vertical-align: bottom ; text-align: left ; border-bottom: double black 2.5pt; padding-left: 20.0px;} td.gnw_label_dline_i25 {font: 12px Arial; vertical-align: bottom ; text-align: left ; border-bottom: double black 2.5pt; padding-left: 25.0px;} td.gnw_label_dline_i30 {font: 12px Arial; vertical-align: bottom ; text-align: left ; border-bottom: double black 2.5pt; padding-left: 30.0px;} td.gnw_label_ulinetop {font: 12px Arial; vertical-align: bottom ; text-align: left ; border-top: solid black 1.0pt;} td.gnw_label_dline {font: 12px Arial; vertical-align: bottom ; text-align: left ; border-bottom: double black 2.5pt;} td.gnw_label_i10 {font: 12px Arial; vertical-align: bottom ; text-align: left ; padding-left: 10.0px;} td.gnw_label_i15 {font: 12px Arial; vertical-align: bottom ; text-align: left ; padding-left: 15.0px;} td.gnw_label_i20 {font: 12px Arial; vertical-align: bottom ; text-align: left ; padding-left: 20.0px;} td.gnw_label_i25 {font: 12px Arial; vertical-align: bottom ; text-align: left ; padding-left: 25.0px;} td.gnw_label_i30 {font: 12px Arial; vertical-align: bottom ; text-align: left ; padding-left: 30.0px;} td.gnw_num {font: 12px Arial; vertical-align: bottom ; text-align: right ; white-space: nowrap ;} td.gnw_num_uline {font: 12px Arial; vertical-align: bottom ; text-align: right ; white-space: nowrap ; border-bottom: solid black 1.0pt;} td.gnw_num_ulinetop {font: 12px Arial; vertical-align: bottom ; text-align: right ; white-space: nowrap ; border-top: solid black 1.0pt;} td.gnw_num_dline {font: 12px Arial; vertical-align: bottom ; text-align: right ; white-space: nowrap ; border-bottom: double black 2.5pt;} td.gnw_num_dlinetop {font: 12px Arial; vertical-align: bottom ; text-align: right ; white-space: nowrap ; border-top: double black 2.5pt;} td.gnw_data {font: 12px Arial; vertical-align: bottom ; text-align: left ; white-space: nowrap ;} td.gnw_data_uline {font: 12px Arial; vertical-align: bottom ; text-align: left ; border-bottom: solid black 1.0pt;} td.gnw_data_dline {font: 12px Arial; vertical-align: bottom ; text-align: left ; border-bottom: double black 2.5pt;} td.gnw_media_caption {font-size: 8pt ; font-family: Verdana, Arial, Helvetica, Geneva, Swiss, SunSans-Regular ;} td.gnw_videotitle {font: bold 12px Arial ; color: #1d5296 ;} ;} ” data-reactid=”38″>

Your list is empty.What to Read NextZacksPR NewswireMilitary.comEngadgetPureWowYahoo FinanceYahoo Finance VideoYahoo FinanceYahoo FinanceYahoo Finance VideoAmerican City Business JournalsMarketWatchYahoo FinanceYahoo FinanceYahoo FinanceYahoo Finance Video

Join mobilsocial social network mobilsocial This article source is Yahoo Finance Article is VIVUS Accelerates the Launch of Telemedicine and Remote …

USA latest News | Canada latest News | Australia latest News

Social Network

accident attorney miami